Not every promising therapy gets a fair shot to become an approved drug. Clinical trials are enormously expensive, so compounds with limited profit potential, weak patent protection, or benefits that don’t fit a disease-specific FDA indication may never reach Phase III. That leaves a fascinating frontier of peptides, small molecules, and biologics backed by compelling biology, promising preclinical research, and sometimes early human evidence, but without definitive clinical trials.

This is the space I document and sometimes explore through informed personal use if I believe the potential benefits justify the risks.